ACRV Acrivon Therapeutics
- 8.230
- -0.860-9.46%
- 8.230
- 0.0000.00%
Acrivon Therapeutics News
Ladenburg Thalmann: Downgraded Acrivon Therapeutics (ACRV.US) rating from buy to neutral.
Ladenburg Thalmann: Downgraded Acrivon Therapeutics (ACRV.US) rating from buy to neutral.
Ladenburg Thalmann Downgrades Acrivon Therapeutics to Neutral
Acrivon Therapeutics (ACRV) Price: 8.28, Change: -0.18, Percent Change: -2.13
Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Acrivon Therapeutics, Inc. (ACRV)
Acrivon Therapeutics Is Maintained at Outperform by BMO Capital
Acrivon Therapeutics Is Maintained at Outperform by BMO Capital
Acrivon Therapeutics Price Target Raised to $25.00/Share From $18.00 by BMO Capital
Acrivon Therapeutics Price Target Raised to $25.00/Share From $18.00 by BMO Capital
BMO Capital Maintains Outperform on Acrivon Therapeutics, Raises Price Target to $25
BMO Capital analyst Etzer Darout maintains Acrivon Therapeutics with a Outperform and raises the price target from $18 to $25.
Buy Rating on Acrivon Therapeutics With Increased Target Price Amid Promising ACR-368 Trial Data
BMO Capital analyst Etzer Darout reiterated a Buy rating on Acrivon Therapeutics, Inc. (ACRV – Research Report) yesterday and set a price target of $25.00.
Acrivon Therapeutics: Strong Buy on Impressive Clinical Outcomes and Market Potential
Piper Sandler Adjusts Price Target on Acrivon Therapeutics to $30 From $26, Keeps Overweight Rating
Piper Sandler Adjusts Price Target on Acrivon Therapeutics to $30 From $26, Keeps Overweight Rating.
Acrivon Therapeutics Is Maintained at Overweight by Piper Sandler
Acrivon Therapeutics Is Maintained at Overweight by Piper Sandler
Acrivon Therapeutics Price Target Raised to $30.00/Share From $26.00 by Piper Sandler
Acrivon Therapeutics Price Target Raised to $30.00/Share From $26.00 by Piper Sandler
Piper Sandler Maintains Overweight on Acrivon Therapeutics, Raises Price Target to $30
Piper Sandler analyst Joseph Catanzaro maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Overweight and raises the price target from $26 to $30.
HC Wainwright & Co. : The Acrivon Therapeutics (ACRV.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $20.00.
HC Wainwright & Co. : The Acrivon Therapeutics (ACRV.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $20.00.
HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $20 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and maintains $20 price target.
Acrivon Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/25/2024 85.87% HC Wainwright & Co. → $20 Reiterates Buy → Buy 04/05/2024 30.11% Ladenburg Thalmann $18
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Acrivon Therapeutics, Inc. (ACRV) and Gain Therapeutics (GANX)
Acrivon Therapeutics: Strong Buy Recommendation on Impressive AP3 Platform and ACR-368 Data Validation
Acrivon Therapeutics' Shares Climb 14% on Plans to Present Cancer Test Data
By Adam L. Cataldo Shares of Acrivon Therapeutics advanced in post-market trading after the biopharmaceutical company said it would present clinical trial data in connection with a biomarker test for
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersAcrivon Therapeutics (NASDAQ:ACRV) stock rose 12.3% to $10.67 during Wednesday's after-market session. The market value of their outstanding shares is at $329.4 million. Amarin Corp (NASDAQ:AMR
Acrivon Therapeutics Reports Breakthrough Results and Solid Finances
Analysis
Price Target
No Data
